A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies

Trial Profile

A Phase 1, Open-label, Dose-escalation Study of SEA-CD40 in Adult Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Apr 2018

At a glance

  • Drugs SEA CD40 (Primary)
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Solid tumours
  • Focus Adverse reactions
  • Sponsors Seattle Genetics
  • Most Recent Events

    • 12 Mar 2018 Planned number of patients changed from 290 to 350.
    • 12 Mar 2018 Planned End Date changed from 1 Jul 2021 to 1 Sep 2022.
    • 12 Mar 2018 Planned primary completion date changed from 1 Apr 2020 to 1 Jun 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top